NeoVirTech opens a new laboratory at the Toulouse Cancer Research Center (CRCT)

NeoVirTech provides access to its ANCHORTM technology platform to develop disruptive models for the investigation of cancer-associated mechanisms and the preclinical development of oncolytic virotherapies.

More specifically, NeoVirTech and CRCT Team 10 aim to develop a rapid and reliable theranostic platform to ensure the efficacy of oncolytic virotherapies in cancer patients.

Long-term collaboration will ensure patient benefits and reduce the time to decision for individualised cancer therapies.

VirHealth and NeoVirTech join their virology expertise to provide customers one of the most extended virus disinfection measurement and R&D platform in France and in Europe. This alliance will allow the partners to combine their respective expertise in an integrated offer dedicated to increase knowledge in virus persistence in the environment, virus disinfection procedure and to provide customer state of the art models for the measurement of disinfection procedures using innovative and standardized approaches.